FindTrial
Sign In

The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables

The Effect of Amiloride and Spironolactone on Renovascular and Cardiovascular Variables in Patients With Essential Hypertension in a Doubleblinded, Randomized, Placebo-controlled, Crossover Study.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01195805
Acronym
hass
Enrollment
25
Registered
2010-09-06
Start date
2010-08-31
Completion date
2015-08-31
Last updated
2015-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Hypertension

Keywords

Blood pressure, PWV, HRV, PWV, potassium

Brief summary

The investigators wish to study the effect of retaining potassium. The participants have essential hypertension. The test substances are Amiloride, Spironolactone and placebo. The participants will ingest tablets for 28 days before being examined. We will perform a 24 hours urine collection, 24-hours bloodpressure measurement, blood and urine samples and we also examine the patient using a SphygmoCor.

Detailed description

Purpose of the study is to examine the effect of amiloride and spironolactone on 1. Renal function (GFR, u-AQP2, u-ENaCβ, u-cAMP, u-PGE2, CH20, FENa, FEK), 2. Pulsewave velocity, augmentation index central bloodpressure, 3. Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and 4. Ambulatory bloodpressure

Interventions

DRUGSpironolactone

1 tablet twice a day for 28 days

OTHERPlacebo

1 tablet twice a day for 28 days

DRUGAmiloride

1 tablet twice a day for 28 days

Sponsors

Regional Hospital Holstebro
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* hypertension, * BMI 18,5-30, * non-smoker

Exclusion criteria

* Smoking * Not using contraceptives * Other illnesses * Drug or alcohol abuse

Design outcomes

Primary

MeasureTime frame
Bloodpressure24-hours and examination

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026